AbbVie's supplemental new drug application for ibrutinib, a product for treating chronic graft vs. host disease (cGVHD) after failure of one or more lines of systemic therapy, has received FDA approval. Read More »

Daiichi Sankyo Inc. recently announced the enrollment of the first person for its Eliminate-AF study. Read More »

Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »

Pfizer Inc.'s supplemental New Drug Application (sNDA) for Ibrance, its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, has been approved by the U.S. Food and Drug Administration. Read More »

Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5. Read More »

Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »

The paper "Radioimmunotherapy for Acute Myeloid Leukemia Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase” was presented at the American Association for Cancer Research (AACR) meeting by Panacea Pharmaceuticals on April 3. Read More »

Teaming up to enhance North Carolina’s public health outcomes, Purdue Pharma of Stamford, Connecticut; nationwide Project Lazarus; and Safe Kids North Carolina recently entered a three-way collaboration via the North Carolina Disposal Initiative (NCDI). Read More »

To treat some of Huntington disease’s harshest symptoms and help restore quality of life to those suffering from the rare, fatal neurodegenerative disease, the U.S. Food and Drug Administration recently approved a medication created by Teva Pharmaceutical Industries. Read More »

Health care supply distributor McKesson Corp. of San Francisco has completed its acquisition of CoverMyMeds LLC, an Ohio-based source of electronic authorization technology for medical providers and pharmacists. Read More »

Change Healthcare recently announced the unveiling of InterQual 2017, the company’s flagship clinical decision support solution. Read More »

Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »

Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »

Amgen recently announced that the company submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for Xgeva (denosumab). The company also seeks approval from the European Medicines Agency (EMA). Read More »

The European Medicines Agency has accepted a Marketing Authorization Application for brexpiprazole, and its review is anticipated in the second quarter of 2018.  Read More »

Acorda Therapeutics Inc. recently announced that the United States District Court for the District of Delaware invalidated four of its patents related to Ampyra extended release tablets. Read More »

Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »

Mylan N.V. has acquired the global rights to Cold-EEZE, a cold remedy line of products, from ProPhase Labs Inc. Read More »

Allergy & Asthma Network and Avella Specialty Pharmacy have released a white paper underscoring latex allergy risks and how that relates to the health care industry. Read More »

Mylan N.V. recently released a brief statement regarding the status of its Abbreviated New Drug Application for its generic iteration of GlaxoSmithKline's Advair Diskus bronchodilator product. Read More »